

Technical Note

Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length

Ta-Chun Cheng, Kuo-Hsiang Chuang, Michael Chen, Hsin-Ell Wang, Shey-Cherng Tzou, Yu-Cheng Su, Chih-Hung Chuang, Chien-Han Kao, Bing-Mae Chen, L. S. Chang, Steve R Roffler, and Tian-Lu Cheng

Bioconjugate Chem., **Just Accepted Manuscript** • DOI: 10.1021/bc3006144 • Publication Date (Web): 09 Jul 2013

Downloaded from <http://pubs.acs.org> on July 19, 2013

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3
4 **Sensitivity of PEGylated interferon detection by anti-polyethylene glycol**
5
6
7 **(PEG) antibodies depends on PEG length**
8

9 Ta-Chun Cheng^{1#}, Kuo-Hsiang Chuang^{2#}, Michael Chen³, Hsin-Ell Wang⁴, Shey-Cherng Tzou⁵,
10
11 Yu-Cheng Su^{6,7}, Chih-Hung Chuang⁸, Chien-Han Kao¹, Bing-Mae Chen⁷, Long-Sen Chang⁹,
12
13 Steve R. Roffler^{7*} and Tian-Lu Cheng^{9,10*}
14
15

16
17 ¹Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;

18 ²Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan;

19 ³Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical
20

21 University

22 ⁴Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming
23 University, Taipei, Taiwan;

24 ⁵Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu,
25 Taiwan;

26 ⁶Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan;

27 ⁷Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan;

28 ⁸Institutes of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan;

29 ⁹Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan;

30 ¹⁰Department of Biomedical Science and Environmental Biology, Kaohsiung Medical
31 University, Kaohsiung, Taiwan.
32
33

34
35 *Correspondence:

36
37 Dr. Tian-Lu Cheng, Department of Biomedical and Environmental Biology, Kaohsiung

38 Medical University, No. 100, Shiquan 1st Road, Kaohsiung City 80708, Taiwan. And Institute

39 of Biomedical Science, National Sun Yat-Sen University, No.70, Lianhai Rd., Kaohsiung City

40 804, Taiwan. Phone: 886-7-3121101-2360; Fax: 886-7-3227508; E-mail: tlcheng@kmu.edu.tw
41
42

43
44 Dr. Steve Roffler, Institute of Biomedical Sciences, Academia Sinica, No.128, Sec. 2,
45

46 Academia Rd., Taipei City 115, Taiwan. Phone: 886-2-2652-3079; Fax: 886-2-2782-9142;
47

48 E-mail: sroff@ibms.sinica.edu.tw
49
50

51 #equal contribution
52
53
54
55
56
57
58
59
60

Abstract

Attachment of poly(ethylene glycol) to proteins can mask immune epitopes to increase serum half-life, reduce immunogenicity, and enhance in vivo biological efficacy. However, PEGylation mediated epitope-masking may also limit sensitivity and accuracy of traditional ELISA. We previously described an anti-PEG-based sandwich ELISA for universal assay of PEGylated molecules. Here, we compared the quantitative assessment of PEGylated interferons by anti-PEG and traditional anti-interferon sandwich ELISA. The detection limits for PEG-Intron[®] (12k-PEG) and Pegasys[®] (40k-PEG) were 1.9 and 0.03 ng/mL for anti-PEG ELISA compared to 0.18 and 0.42 ng/mL for traditional anti-interferon sandwich ELISA. These results indicate that the sensitivity of anti-PEG sandwich ELISA was insensitive to PEGylation mediated epitope-masking and increased in proportion to the length of PEG. By contrast, PEG-masking interfered with detection by traditional anti-interferon sandwich ELISA. Human and mouse serum did not affect the sensitivity of anti-PEG ELISA but impeded traditional anti-interferon sandwich ELISA. The anti-PEG sandwich ELISA was comparable to anti-interferon sandwich ELISA and radioassay of ¹³¹I-Pegasys[®] in pharmacokinetic studies in mice. The anti-PEG sandwich ELISA provides a sensitive, accurate and convenient quantitative measurement of PEGylated protein drugs.

Introduction

Polyethylene glycol (PEG) is a highly water-soluble and non-toxic polymer that is approved by the Food and Drug Administration (FDA) for human use ¹. Covalent linkage of PEG to proteins can shield binding sites, minimize proteolytic cleavage and mask immunogenic sites, thereby prolonging the circulation time in the human body, improving therapeutic efficacy and reducing the injection frequency to enhance patients' quality of life ²⁻⁵. Based on these advantages, PEGylation has become one of the most useful pharmaceutical technologies to create protein drugs with markedly improved therapeutic properties compared with their unconjugated counter parts ^{6,7}. For example, the clinical treatment of chronic hepatitis B and C with interferon- α -2a (Roferon[®]-A) has been limited by the short half-life of IFN- α in patients (less than 12 hours), resulting in the need to administer repeated injections at least three times a week to achieve the desired therapeutic benefits. PEGylated interferons, including PEG-Intron[®] (linear PEG_{12K}-interferon- α -2b) and Pegasys[®] (branched PEG_{40K}-interferon- α -2a), display dramatically increased half-lives, allowing decreased dosing to once per week ⁸. How to efficiently assess the pharmacokinetics of PEGylated drugs is an important issue with the ever increasing number of such compounds under development.

Measurement of drug concentrations in serum samples is important for clinical drug development and assessment of drug pharmacokinetics and bioavailability. However, attachment of PEG molecules to proteins may mask antibody-binding epitopes that interfere

1
2
3
4 with detective sensitivity using protein-specific antibodies ^{9,10}. We previously reported that an
5
6 anti-PEG based sandwich ELISA using anti-PEG monoclonal antibodies (AGP4 and 3.3) can
7
8 detect a wide range of PEGylated molecules including Pegasys, PEG-Intron, Neulasta and
9
10 PEG-Lipo-Dox with ng/mL sensitivities ¹⁰. Based on those results, we hypothesized that the
11
12 anti-PEG sandwich ELISA is not affected by PEG generated epitope-masking.
13
14
15
16
17

18 Here, we compared the measurement of PEGylated interferon by anti-PEG based and
19
20 traditional anti-interferon based sandwich ELISAs. We first examined the detection limits of
21
22 the anti-PEG and anti-interferon based sandwich ELISAs. We also investigated whether human
23
24 or mouse serum affected detection sensitivities of the assays. Finally, we compared the
25
26 measurement of ¹³¹I labeled Pegasys (¹³¹I-Pegasys) in the serum of mice by radioactive
27
28 quantification or ELISA. The anti-PEG based sandwich ELISA displayed high sensitivity and
29
30 was free from interference by serum proteins, suggesting that anti-PEG ELISA is particularly
31
32 suitable as a standard method for measuring the pharmacokinetics of PEGylated protein drugs
33
34 in pre-clinical and clinical study.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Reagents and animals

Maxisorp flat-bottom 96-well plates were purchased from Nunc, NY, USA. Skim milk was purchased from BD Difco™, NJ, U.S.A. Pegasys® and Roferon®-A were from Roche, NJ, USA. PEG-Intron® was from Merck, NY, USA. Horseradish peroxidase-conjugated streptavidin were from Jackson ImmunoResearch Laboratories, PA, U.S.A. 2,2'-azino-bis-[3-ethylbenzthiazoline- 6-sulfonic acid] (ABTS) and 30% hydrogen peroxide were from Sigma-Aldrich, MO, USA. 5-week-old BALB/c female mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan, and were bred in the specific pathogen-free facility at Kaohsiung Medical University.

Sandwich ELISA

In the anti-PEG sandwich ELISA¹⁰, Maxisorp flat-bottom 96 well plates were coated with 50 µl/well of AGP4 (20 µg/ml) in coating buffer (100 mM Na₂CO₃, pH 8.0) at 37 °C for 2 h and then at 4 °C for overnight. The wells were blocked with 5% skim milk in PBS at 37°C for 2 h and then washed twice in phosphate-buffered saline (PBS). Non-modified interferon α-2a (Roferon®-A), PEG_{12K}-interferon α-2b (PEG-Intron®) and PEG_{40K}-interferon α-2a (Pegasys®) were serially diluted in dilution buffer (2% skim milk in PBS), added to wells (50 µl/well) and incubated at room temperature for 2 h. After washing with PBS three times, the wells were sequentially incubated with 50 µl/well of biotinylated anti-PEG antibody (3.3-biotin, 5 µg/ml

1
2
3
4 in dilution buffer) and 50 μ l/well horseradish peroxidase (HRP)-conjugated streptavidin
5
6
7 (1 μ g/ml in dilution buffer). The wells were washed with PBS eight times and 100 μ l of
8
9
10 substrate solution (0.4 mg/ml ABTS, 0.01% hydrogen peroxide in 100 mM phosphate-citrate
11
12 buffer, pH 4.0) was added and incubated in the dark at room temperature for 30 min. The
13
14
15 absorbance in the wells was measured at 405 nm using a MRX microplate reader (Dynerx
16
17
18 Technologies, VA, U.S.A.).
19

20
21
22 Anti-interferon sandwich ELISA was performed using the VeriKineTM Human IFN- α
23
24
25 ELISA Kit (catalog number 41100; Pestka Biomedical Laboratories, NJ, U.S.A.). All three
26
27
28 interferons were serially diluted with dilution buffer and added to wells (100 μ l/well) and
29
30
31 incubated at room temperature for 1 h, following the manufacturer's guidelines. After washing
32
33
34 with wash solution, the well was stained with 100 μ l/well of diluted antibody concentrate at
35
36
37 room temperature for 1 h followed by staining with 100 μ l/well of diluted HRP conjugate.
38
39
40 After the wells were washed four times, 100 μ l of 3,3',5,5'-tetramethylbenzidine (TMB)
41
42
43 substrate was added to the wells. Color development was stopped by the addition of 100 μ l of
44
45
46 stop solution. The absorbance in the wells was measured at 450 nm using the MRX microplate
47
48
49 reader.
50

51 52 **Detection of Pegasys[®] in serum by ELISA**

53
54

55 To investigate the influence of serum in sandwich ELISA, human serum was obtained
56
57
58 from three healthy volunteers and mouse serum was collected from five BALB/c female mice.
59
60

1
2
3
4 Endogenous anti-PEG antibodies were not detected in any of the serum samples. Pegasys[®] in
5
6 dilution buffer containing 0-20% human or murine serum was measured by the anti-PEG and
7
8 the anti-interferon ELISAs as described above.
9
10

11 12 13 14 15 **Analysis of Pegasys[®] stability in human serum** 16

17
18 A 10 µg/ml aliquot of Pegasys[®] was incubated with DEME buffer contain 50% human
19
20 serum and 1% penicillin-streptomycin at 37°C. Samples collected at different times (0, 24, 48,
21
22 72, and 96 h) were electrophoresed in a 7% sodium-dodecyl sulfate polyacrylamide gel under
23
24 reducing conditions and then transferred onto a nitrocellulose paper (Millipore). After blocking
25
26 in 5% skim milk, the blot was incubated with 5 µg/ml AGP4-biotin in PBS containing 2% skim
27
28 milk for 1 h at room temperature. The blot was washed 3 times with PBS-T (PBS containing
29
30 0.05% Tween-20) and twice with PBS before incubation with streptavidin-HRP for 1 h at room
31
32 temperature. After washing three times with PBS-T and twice with PBS, specific bands were
33
34 visualized by ECL detection according to the manufacturer's instructions (Pierce, Rockford, IL,
35
36 U.S.A.).
37
38
39
40
41
42
43
44
45
46
47

48 **Pharmacokinetic analysis of ¹³¹I-Pegasys[®] in mice** 49

50
51 For comparison of anti-PEG sandwich ELISA with existing methods, the
52
53 pharmacokinetics of Pegasys[®] in mice was analyzed by the anti-PEG and the anti-interferon
54
55 ELISAs and a traditional radioassay as a reference method. ¹³¹I-Pegasys[®] were synthesized by
56
57
58
59
60

1
2
3
4 Hsin-Ell Wang, Ph.D. (Department of Medical Radiation Technology and Institute of
5
6
7 Radiological Sciences, National Yang-Ming University, Taiwan). BALB/c mice were
8
9
10 intravenously (i.v.) injected with 740 kBq of ^{131}I -Pegasys[®] (containing 5 μg of Pegasys[®]).
11
12 Serum was isolated from venous blood of the mice at the indicated time points after injection
13
14 (1, 2, 4, 8, 16, 24, 48 and 72 hr.) and analyzed by the sandwich ELISAs described above. The
15
16 radioactivity of ^{131}I -Pegasys[®] in the blood was independently determined by Wallac 1470
17
18 Wizard gamma counter (Perkin-Elmer, MA, USA.). Results (mean \pm SD) are expressed as the
19
20 concentration of Pegasys[®] in serum ($\mu\text{g}/\text{mL}$).
21
22
23
24
25
26
27

28 **Statistical Analysis**

29
30
31 To determine whether serum affected the measurement of ELISA, statistical comparisons
32
33 were made using one-way ANOVA followed by Dunnett's multiple comparison tests
34
35 between control group (0%) and test groups (2, 5 and 20%). Statistical significance was
36
37 defined as $p < 0.05$.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Quantification of PEGylated protein drugs by anti-PEG and anti-interferon sandwich

ELISAs

To evaluate the utility of anti-PEG and anti-interferon sandwich ELISAs, defined concentrations of a non-PEGylated interferon (Roferon[®]-A), a 12K-PEG modified interferon (PEG-Intron[®]), and a 40K-PEG modified interferon (Pegasys[®]) were measured by AGP4/3.3 anti-PEG sandwich ELISA¹⁰ and a commercial VeriKine[™] Human IFN- α ELISA Kit. Figure 1A shows that the detection limits of the anti-PEG sandwich ELISA were 1.9 ng/mL for PEG-Intron[®] and 0.03 ng/mL for Pegasys[®]. As expected, Roferon[®]-A was not detected by the anti-PEG sandwich ELISA since Roferon[®]-A does is not modified with PEG molecules. The detected limitation of Roferon[®]-A, PEG-Intron[®], and Pegasys[®] were 0.12, 0.18, 0.42 ng/mL as measured by the VeriKine[™] Human IFN- α ELISA Kit (Fig. 1B). Thus, the detection sensitivity of the anti-PEG sandwich ELISA increased as the size of PEG chains on interferon increased whereas the anti-interferon sandwich ELISA showed the opposite trend.

Influence of serum on anti-PEG and anti-interferon sandwich ELISAs

To investigate the effect of serum on detection sensitivity, defined concentrations of Pegasys[®] were incubated in 0, 5 or 20% human or mouse serum before assay by anti-PEG sandwich ELISA or the VeriKine[™] Human IFN- α ELISA. The presence of 5% or 20% mouse

1
2
3
4 (Fig. 2A) or human (Fig. 2C) serum did not affect the sensitivity of the anti-PEG ELISA. By
5
6
7 contrast, 20% mouse (Fig. 2B) or human (Fig. 2D) serum significantly ($p < 0.05$) decreased the
8
9
10 sensitivity of the IFN- α ELISA. To assess the stability of the linkage between PEG and
11
12 interferon in serum, Pegasys[®] (10 $\mu\text{g}/\text{mL}$) was incubated with 50% human serum for 0, 24, 48,
13
14
15 72, and 96 hours. The stability of Pegasys[®] in human serum was detected by western blot using
16
17
18 biotinylated anti-PEG antibody (AGP4-Biotin). Figure 2E showed that Pegasys[®] did not
19
20
21 dissociate in human serum even after 96 hours, indicating that the linkage between PEG and
22
23
24 interferon is very stable in serum. These results indicate that the presence of serum does not
25
26
27 hamper detection of PEGylated proteins by anti-PEG sandwich ELISA.
28
29
30
31
32

33 **Pharmacokinetics of ¹³¹I-Pegasys[®] determined by anti-PEG and anti-interferon sandwich** 34 35 **ELISAs**

36
37
38 To investigate the feasibility of using anti-PEG sandwich ELISA to measure PEGylated
39
40
41 interferon in pharmacokinetic studies, 740 kBq (5 μg) of ¹³¹I-labeled Pegasys[®] was i.v. injected
42
43
44 into BALB/c mice. Venous sera were collected at the indicated times and the concentrations of
45
46
47 ¹³¹I-Pegasys[®] were determined by anti-PEG ELISA, VeriKine[™] Human IFN- α ELISA and a
48
49
50 gamma counter which directly determined levels of radioactivity in the sera. Figure 3 shows
51
52
53 that the pharmacokinetics of ¹³¹I-Pegasys[®] determined using the anti-PEG based ELISA ($t_{1/2}$ =
54
55
56 13.14 h) was similar to the half-life measured by the Human IFN- α ELISA Kit ($t_{1/2}$ = 12.44 h).
57
58
59
60

1
2
3
4 Lower concentrations and a shorter half-life ($t_{1/2} = 7.64$ h) were determined by measuring the
5
6
7 radioactivity in serum samples. Based on these results, we conclude that the anti-PEG based
8
9
10 sandwich ELISA is a highly efficient method to measure the pharmacokinetics of PEGylated
11
12
13 protein drugs.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The shielding effect of PEG can mask antibody-binding epitopes on proteins, resulting in weaker interactions with detection and capture antibodies during ELISA, thereby decreasing assay sensitivity. We demonstrated that an anti-PEG sandwich ELISA to detect PEGylated interferon is superior to a commercial anti-interferon sandwich ELISA. The anti-PEG sandwich ELISA displayed high sensitivity and was not inhibited by PEG-mediated epitope masking or the presence of serum in samples. The sensitivity of the anti-PEG sandwich ELISA increased with the length of PEG chains attached to interferon. The concentration of ^{131}I -Pegasys[®] in serum samples measured by anti-PEG sandwich ELISA was comparable to a commercial anti-interferon sandwich ELISA and to direct measurement of serum radioactivity. These data indicate that the anti-PEG sandwich ELISA may reliably measure PEGylated proteins for drug development or in clinical trials.

PEGylation of proteins and peptides is a Food & Drug Administration (FDA) approved technology to increase half-life and therapeutic efficacy^{5,11-13}. Many PEGylated protein drugs are now available for clinical use, including PEGylated anti-tumor necrosis factor α antibody (PEG-anti-TNF α)¹⁴, PEGylated anti-interleukin-8 (PEG-anti-IL8)¹⁵, PEGylated Toll like receptor 7 ligands⁵ and PEGylated granulocyte colony stimulating factor (PEG-G-CSF)¹⁶. The anti-PEG sandwich ELISA employs anti-PEG antibodies for PEG-dependent/target molecule-independent quantization of any PEGylated compound. Our previous results showed

1
2
3
4 that PEG-G-CSF (Neulasta[®]) and PEGylated nanoparticles such as PEG-Qdot[®] 525 and
5
6 Lipo-Dox[®] were also detected by the anti-PEG sandwich ELISA^{10,17}. In this study, we used the
7
8 anti-PEG sandwich ELISA to quantify two types of PEGylated interferons (PEG-Intron[®] and
9
10 Pegasys[®]). Taken together, our results indicate that anti-PEG sandwich ELISA can be used for
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Site-specific monoPEGylation is accepted as good manufacturing practice (GMP) for
clinical use^{18,19}. Protein drugs are usually conjugated with single high molecular weight (40
kDa) PEG molecule to achieve homogeneous modification and improved therapeutic efficacy
^{7,16}. For example, attachment of a branched PEG polymer with an average molecular mass of
40,000 to interferon increased its serum half-life by 330-fold in rats²⁰. HCV patients treated
once per week with Pegasys[®] experienced greater decreases in liver inflammation than patients
treated with standard three-times-weekly interferon⁷, thereby increasing patient compliance
and quality of life. However, long chain PEG molecules may mask antibody-binding epitopes
on proteins^{9,10,21} and decrease the sensitivity of traditional protein-specific ELISA (Fig. 1B).
We used anti-PEG antibodies to generate a quantitative platform for PEGylated drugs in which
PEGylated proteins are quantified by surface-linked PEG molecules. Our previous results
demonstrated that a single long chain PEG chain contains multiple epitopes for binding by
anti-PEG antibodies^{10,22,23}. Detection sensitivity is proportional to the length of the PEG chain.
The anti-PEG sandwich ELISA is therefore particularly suited for measuring protein drugs

1
2
3
4 modified with long chain PEG molecules.
5

6
7 Development of a quantitative method that is insensitive to the presence of serum in
8
9 samples is important for in vivo pharmacokinetic studies of drugs. The half-life of a drug in
10
11 blood is a key factor in pharmacokinetic analysis and is related to absorption and distribution
12
13 of the drug after administration. However, serum interference is an often encountered obstacle
14
15 in ELISA assay development ^{24,25}. For example, some serum proteins, such as heterophilic
16
17 antibodies, can cause high non-specific binding in virus antibody ELISAs ^{26,27} and may hamper
18
19 detection of proteins by epitope-masking ²⁸. In addition, serum can seriously lower the
20
21 detection sensitivity of traditional ELISA ²⁹. We also observed here that serum impeded the
22
23 detection sensitivity of the anti-interferon sandwich ELISA. By contrast, the presence of mouse
24
25 or human serum in samples ^{10,22,23} did not decrease the sensitivity of the anti-PEG sandwich
26
27 ELISA.
28
29
30
31
32
33
34
35
36
37

38
39 The covalent linkage between PEG and interferon in Pegasys[®] is very stable in human
40
41 serum (Fig. 2E). The lower concentration of ¹³¹I-Pegasys[®] in serum determined by measuring
42
43 radioactivity is unlikely due to dissociation of the linkage between PEG and interferon, but
44
45 rather likely resulted from deiodination of ¹³¹I from interferon. Iodine can be hydrolyzed from
46
47 radiolabeled proteins by iodotyrosine deiodinase, resulting in underestimation of protein
48
49 concentrations ^{30,31}. This may explain the higher interferon concentrations detected by the
50
51 anti-PEG and anti-interferon sandwich ELISAs (Fig. 3). In our study, anti-IFN sandwich
52
53
54
55
56
57
58
59
60

1
2
3
4 ELISA was used as a standard assay kit to compare with anti-PEG sandwich ELISA to
5
6 determine the pharmacokinetics of Pegasys[®] in mice. However, the anti-IFN sandwich ELISA
7
8 cannot sensitively detect PEG-modified interferon, especially Pegasys[®] (Fig. 1B), and the
9
10 presence of mouse serum also interfered in the sensitivity of anti-IFN sandwich ELISA (Fig.
11
12 2B). Similar to previous studies²⁰, we used a high dose of Pegasys[®] (5 μg per mouse) to allow
13
14 detection at later time points by anti-IFN sandwich ELISA. By contrast, the anti-PEG sandwich
15
16 ELISA can detect PEGylated interferon very sensitively with a detection limit of 0.03 ng/mL
17
18 for Pegasys[®] (Fig. 1A). In addition, the presence of 20% of mouse serum did not affect the
19
20 sensitivity of anti-PEG sandwich ELISA (Fig. 2A). Another potential advantage of the
21
22 anti-PEG ELISA is that endogenous cytokines in sera will not be detected (as shown for
23
24 Roferon[®]-A in Fig. 1A). By contrast, traditional cytokine ELISAs can also detect circulating
25
26 cytokines, thereby overestimating PEGylated cytokine concentrations^{32,33}. Thus, anti-PEG
27
28 sandwich ELISA may more precisely measure PEGylated drug concentrations as compared to
29
30 traditional methods.
31
32
33
34
35
36
37
38
39
40
41
42
43

44 In summary, we demonstrate that the anti-PEG sandwich ELISA can be used to quantify
45
46 PEGylated protein drugs. The advantages of anti-PEG sandwich ELISA are (1) it is insensitive
47
48 to PEG-mediated epitope masking, (2) it is insensitive to serum interference, and (3) it can
49
50 quantify any PEGylated molecule. The sensitivity of detection is proportional to the length of
51
52 the PEG conjugated on the protein drug, so the ELISA is most suitable for proteins that contain
53
54
55
56
57
58
59
60

1
2
3
4 a single long PEG molecule or multiple short PEG molecules^{10,22,23}. The anti-PEG sandwich
5
6
7 ELISA may also be superior when endogenous compounds can be recognized by traditional
8
9
10 ELISA. The universality and convenience of the anti-PEG sandwich ELISA suggests that this
11
12
13 assay offers a standard method for quantification of PEGylated proteins in pre-clinical and
14
15
16 clinical pharmacokinetic studies.
17
18
19
20
21
22
23

24 **Acknowledgements**

25
26
27 This work was supported by grants from the National Research Program for
28
29
30 Biopharmaceuticals, National Science Council, Taipei, Taiwan (NSC101-2325-B-037-001,
31
32
33 NSC101-2321-B-037-001), the Department of Health, Executive Yuan, Taiwan
34
35
36 (DOH102-TD-C-111-002) and the Grant of Biosignature in Colorectal Cancers, Academia
37
38
39 Sinica, Taiwan and NSYSU-KMU Joint Research Project (NSYSUKMU102-P035)
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- (1) Fu, J., Fiegel, J., Krauland, E., and Hanes, J. (2002) New polymeric carriers for controlled drug delivery following inhalation or injection. *Biomaterials* 23, 4425-4433.
- (2) Pisal, D. S., Kosloski, M. P., and Balu Iyer, S. V. (2010) Delivery of therapeutic proteins. *Journal of Pharmaceutical Sciences* 99, 2557-2575.
- (3) Jev evar, S., Kunstelj, M., and Porekar, V. G. (2010) PEGylation of therapeutic proteins. *Biotechnology journal* 5, 113-128.
- (4) Werle, M., and Bernkop-Schnurch, A. (2006) Strategies to improve plasma half life time of peptide and protein drugs. *Amino Acids* 30, 351-367.
- (5) Chan, M., Hayashi, T., Mathewson, R. D., Yao, S., Gray, C., Tawatao, R. I., Kalenian, K., Zhang, Y., Hayashi, Y., Lao, F. S., Cottam, H. B., and Carson, D. A. (2011) Synthesis and characterization of PEGylated toll like receptor 7 ligands. *Bioconjug Chem* 22, 445-454.
- (6) Jo, Y. W., Youn, Y. S., Lee, S. H., Kim, B. M., Kang, S. H., Yoo, M., Choi, E. C., and Lee, K. C. (2006) Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. *Int J Pharm* 309, 87-93.
- (7) Rajender Reddy, K., Modi, M. W., and Pedder, S. (2002) Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. *Adv Drug Deliv Rev* 54, 571-586.
- (8) Matthews, S. J., and McCoy, C. (2004) Peginterferon alfa-2a: a review of approved and investigational uses. *Clin Ther* 26, 991-1025.
- (9) Hershfield, M. S., Chaffee, S., Koro-Johnson, L., Mary, A., Smith, A. A., and Short, S. A. (1991) Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. *Proc Natl Acad Sci U S A* 88, 7185-7189.
- (10) Su, Y. C., Chen, B. M., Chuang, K. H., Cheng, T. L., and Roffler, S. R. (2010) Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. *Bioconjug Chem* 21, 1264-1270.
- (11) Harris, J. M., and Chess, R. B. (2003) Effect of pegylation on pharmaceuticals. *Nature Reviews Drug Discovery* 2, 214-221.
- (12) Alconcel, S. N. S., Baas, A. S., and Maynard, H. D. (2011) FDA-approved poly(ethylene glycol)-protein conjugate drugs. *Polymer Chemistry* 2, 1442-1448.
- (13) Kim, T. H., Youn, Y. S., Jiang, H. H., Lee, S., Chen, X., and Lee, K. C. (2011) PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. *Bioconjug Chem* 22, 1631-1637.
- (14) Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M. C., Liu, S., Hua, J., Zhang, Z., Zhou, J., Li, M., Phyu, H., Petti, G., Mendez, M., Janjua, H., Peng, P., Longley, C.,

- 1
2
3 Borowski, V., Mehlig, M., and Filpula, D. (2003) Tailoring structure-function and
4 pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation.
5 *Protein Eng* 16, 761-770.
6
7 (15) Koumenis, I. L., Shahrokh, Z., Leong, S., Hsei, V., Deforge, L., and Zapata, G. (2000)
8 Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific
9 PEGylation with preserved bioactivity. *Int J Pharm* 198, 83-95.
10
11 (16) Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C. (2002)
12 Mono-N-terminal poly(ethylene glycol)-protein conjugates. *Adv Drug Deliv Rev* 54,
13 477-485.
14
15 (17) Cheng, T. L., Cheng, C. M., Chen, B. M., Tsao, D. A., Chuang, K. H., Hsiao, S. W., Lin,
16 Y. H., and Roffler, S. R. (2005) Monoclonal antibody-based quantitation of
17 poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. *Bioconjug*
18 *Chem* 16, 1225-1231.
19
20 (18) Chapman, A. P., Antoniow, P., Spitali, M., West, S., Stephens, S., and King, D. J. (1999)
21 Therapeutic antibody fragments with prolonged in vivo half-lives. *Nat Biotechnol* 17,
22 780-783.
23
24 (19) Natarajan, A., Xiong, C. Y., Albrecht, H., DeNardo, G. L., and DeNardo, S. J. (2005)
25 Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
26 *Bioconjug Chem* 16, 113-121.
27
28 (20) Ramon, J., Saez, V., Baez, R., Aldana, R., and Hardy, E. (2005) PEGylated
29 interferon-alpha2b: a branched 40K polyethylene glycol derivative. *Pharm Res* 22,
30 1374-1386.
31
32 (21) Vugmeyster, Y., Entrican, C. A., Joyce, A. P., Lawrence-Henderson, R. F., Leary, B. A.,
33 Mahoney, C. S., Patel, H. K., Raso, S. W., Olland, S. H., Hegen, M., and Xu, X. (2012)
34 Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies
35 conjugated to linear or branched poly(ethylene glycol). *Bioconjug Chem* 23,
36 1452-1462.
37
38 (22) Tsai, N. M., Cheng, T. L., and Roffler, S. R. (2001) Sensitive measurement of
39 polyethylene glycol-modified proteins. *Biotechniques* 30, 396-402.
40
41 (23) Chuang, K. H., Tzou, S. C., Cheng, T. C., Kao, C. H., Tseng, W. L., Shiea, J., Liao, K.
42 W., Wang, Y. M., Chang, Y. C., Huang, B. J., Wu, C. J., Chu, P. Y., Roffler, S. R., and
43 Cheng, T. L. (2010) Measurement of poly(ethylene glycol) by cell-based
44 anti-poly(ethylene glycol) ELISA. *Anal Chem* 82, 2355-2362.
45
46 (24) Nielsen, K., Kelly, L., Gall, D., Smith, P., Bosse, J., Nicoletti, P., and Kelly, W. (1994)
47 The use of divalent cation chelating agents (EDTA/EGTA) to reduce non-specific
48 serum protein interaction in enzyme immunoassay. *Vet Res Commun* 18, 433-437.
49
50 (25) Stahnke, H., Kittlaus, S., Kempe, G., and Alder, L. (2012) Reduction of matrix effects
51 in liquid chromatography-electrospray ionization-mass spectrometry by dilution of the
52
53
54
55
56
57
58
59
60

- 1
2
3 sample extracts: how much dilution is needed? *Anal Chem* 84, 1474-1482.
- 4 (26) Kricka, L. J. (1999) Human anti-animal antibody interferences in immunological assays.
5 *Clin Chem* 45, 942-956.
- 6 (27) Martins, T. B., Pasi, B. M., Litwin, C. M., and Hill, H. R. (2004) Heterophile antibody
7 interference in a multiplexed fluorescent microsphere immunoassay for quantitation of
8 cytokines in human serum. *Clin Diagn Lab Immunol* 11, 325-329.
- 9 (28) Urbonaviciute, V., Furnrohr, B. G., Weber, C., Haslbeck, M., Wilhelm, S., Herrmann,
10 M., and Voll, R. E. (2007) Factors masking HMGB1 in human serum and plasma. *J*
11 *Leukoc Biol* 81, 67-74.
- 12 (29) DeForge, L. E., Shih, D. H., Kennedy, D., Totpal, K., Chuntharapai, A., Bennett, G. L.,
13 Drummond, J. H., Siguenza, P., and Wong, W. L. (2007) Species-dependent serum
14 interference in a sandwich ELISA for Apo2L/TRAIL. *J Immunol Methods* 320, 58-69.
- 15 (30) Neal, J. C., Stolnik, S., Schacht, E., Kenawy, E. R., Garnett, M. C., Davis, S. S., and
16 Illum, L. (1998) In vitro displacement by rat serum of adsorbed radiolabeled poloxamer
17 and poloxamine copolymers from model and biodegradable nanospheres. *J Pharm Sci*
18 87, 1242-1248.
- 19 (31) Friedman, J. E., Watson, J. A., Jr., Lam, D. W., and Rokita, S. E. (2006) Iodotyrosine
20 deiodinase is the first mammalian member of the NADH oxidase/flavin reductase
21 superfamily. *J Biol Chem* 281, 2812-2819.
- 22 (32) Grassi, J., Roberge, C. J., Frobert, Y., Pradelles, P., and Poubelle, P. E. (1991)
23 Determination of IL1 alpha, IL1 beta and IL2 in biological media using specific
24 enzyme immunometric assays. *Immunol Rev* 119, 125-145.
- 25 (33) Liao, K., Sikkema, D., Wang, C., Chen, K., DeWall, S., and Lee, T. N. (2012)
26 Development and validation of a cell-based SEAP reporter assay for the detection of
27 neutralizing antibodies against an anti-IL-13 therapeutic antibody. *J Immunol Methods*
28 375, 258-263.
- 29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends




Figure 1. Comparison of anti-PEG and anti-IFN sandwich ELISAs for detection of non-modified and PEGylated interferon. Serially diluted Roferon[®]-A(○), PEG-Intron[®] (■) and Pegasys[®] (●) were detected by anti-PEG sandwich ELISA (A) or anti-IFN sandwich ELISA (B), respectively. Representative data from three independent experiments are shown. Bars, SD.




Figure 2. Serum interference in anti-PEG and anti-IFN sandwich ELISAs. Pegasys[®]

serially diluted in 0% (○), 5% (●) or 20% (■) mouse or human serum were detected by the anti-PEG sandwich ELISA (A, C) or anti-IFN sandwich ELISA (B, D). Bars, SD. *, $p < 0.05$; **, $p < 0.01$, Dunnett's multiple comparison tests between control group (0%) and other groups. (E)

The stability of the linkage between PEG and interferon in serum. Pegasys[®] was incubated in 50% human serum for 0 h (lane 2), 24 h (lane 3), 48 h (lane 4), 72 h (lane 5), and 96 h (lane 6). Samples were electrophoresed on a 7% reduced SDS-PAGE gel, transferred to nitrocellulose paper, and probed with AGP4-biotin as described in Materials and Methods. Lane 1, 50% serum as blank control; Lane 7, Pegasys[®] as a positive control. Representative data from three independent experiments are shown.




Figure 3. Serum concentration-time curve of ^{131}I -Pegasys $^{\text{®}}$ i.v. injected into mice. Sera of BALB/c mice (n=4) were collected at the indicated times (1, 2, 4, 8, 16, 24, 48, 72 hours) after i.v. injection of ^{131}I -Pegasys $^{\text{®}}$. The concentration of ^{131}I -Pegasys $^{\text{®}}$ was determined by anti-PEG sandwich ELISA (●), anti-IFN sandwich ELISA (○) or gamma counter (▲). Representative data from three independent experiments are shown. Bars, SD.




Figure 1. Comparison of anti-PEG and anti-IFN sandwich ELISAs for detection of non-modified and PEGylated interferon. Serially diluted Roferon®-A(○), PEG-Intron® (■) and Pegasys® (●) were detected by anti-PEG sandwich ELISA (A) or anti-IFN sandwich ELISA (B), respectively. Representative data from three independent experiments are shown. Bars, SD.

39x18mm (600 x 600 DPI)




Figure 2. Serum interference in anti-PEG and anti-IFN sandwich ELISAs. Pegasys® serially diluted in 0% (○), 5% (●) or 20% (■) mouse or human serum were detected by the anti-PEG sandwich ELISA (A, C) or anti-IFN sandwich ELISA (B, D). Bars, SD. *, $p < 0.05$; **, $p < 0.01$, Dunnett's multiple comparison tests between control group (0%) and other groups. (E) The stability of the linkage between PEG and interferon in serum. Pegasys® was incubated in 50% human serum for 0 h (lane 2), 24 h (lane 3), 48 h (lane 4), 72 h (lane 5), and 96 h (lane 6). Samples were electrophoresed on a 7% reduced SDS-PAGE gel, transferred to nitrocellulose paper, and probed with AGP4-biotin as described in Materials and Methods. Lane 1, 50% serum as blank control; Lane 7, Pegasys® as a positive control. Representative data from three independent experiments are shown. 90x97mm (600 x 600 DPI)






Figure 3. Serum concentration-time curve of ^{131}I -Pegasys $^{\text{®}}$ i.v. injected into mice. Sera of BALB/c mice ($n=4$) were collected at the indicated times (1, 2, 4, 8, 16, 24, 48, 72 hours) after i.v. injection of ^{131}I -Pegasys $^{\text{®}}$. The concentration of ^{131}I -Pegasys $^{\text{®}}$ was determined by anti-PEG sandwich ELISA (\bullet), anti-IFN sandwich ELISA (\circ) or gamma counter (\blacktriangle). Representative data from three independent experiments are shown. Bars, SD.
59x42mm (600 x 600 DPI)

Anti-PEG based sandwich ELISA



Pharmacokinetic Study



50x29mm (300 x 300 DPI)